Caractérisation de l’impact des interactions chimiques sur la variabilité interindividuelle de la toxicocinétique des composés organiques volatiles, et portée sur une approche appliquée de dosimétrie inverse
Human biomonitoring consists in the measurements of chemicals or their metabolites in biological matrices. These biological data are often interpreted by comparison with so-called bio-equivalent values to the toxicological reference values (TRV) which have for the most part been defined through the use of animal models in a context of simple chemical exposure. However, biomonitoring data can result from multi-routes co-exposures to multiple chemical such as Volatile Organic Compounds (VOCs), which can give rise to toxicokinetic interactions in the human body. Physiologically-based pharmacokinetic (PBPK) modeling approaches have been developed to study these interactions. But, their impact on the interindividual variability (IV) of the toxicokinetics of individual substances, and the evaluation of the toxic risk of chemical contaminants, that may result from multi-routes exposure, have only been sparsely studied. Further, the scientific literature suggests an approach for the direct reconstruction of external chemical exposure from blood measurements of VOCs’ parent compounds. This is generally done for 70-kg adults by the use of appropriate PBPK models, combined with a probability calculation approach, in a process called “reverse dosimetry”. But the uncertainties associated with estimates of external exposure made using this approach from biological spot measurements collected during health surveys have hardly been studied. The current doctoral research aims to characterize the impact of multi-routes chemical co-exposures on the interindividual variability of toxicokinetics, in order to account it for in the development in this thesis of applied approaches of reverse dosimetry. First, we built multi-routes probabilistic PBPK models for two mixtures (benzene, toluene, ethylbenzene and m-xylene (BTEX) on one hand, and trichloroethylene and vinyl chloride (TCE-VC) on the other hand) for human subpopulations of different ages (including one of adults). These models were coupled with Monte Carlo simulations in order to explore the impact of multi-routes co-exposures on the IV of the toxicokinetics of individual compounds at ‘low’ or ‘high’ exposures. Variability indices (VIs) were calculated as the ratio of the 95th percentile value of the distribution of an internal dose in the other subpopulations studied to the 50th percentile value of the same distribution in adults. In a second step, we refined the existing reverse dosimetry approach by developing probabilistic inhalation PBPK models for Canadian subpopulations (of different age, body weight and size) whose blood toluene measurements were collected during the third cycle of Canadian Health Measures Survey (CHMS-3), in order to reconstruct their corresponding external exposure. Finally, we have developed an individual reverse dosimetry approach to estimate external exposure to toluene from urinary measurements of one of its metabolites (S-benzylmercapturic acid or BMA) reported in Canadian individuals. Two techniques were tested here for this estimation: estimating toluene exposure from spot measurements of urinary BMA of a full day obtained in each individual and estimating exposure from an individual measurement of urinary BMA performed on 24-h urines. The individual approach allowed us to propose a method to quantify the uncertainty, that means the possible error, on the estimates of external exposure made by reverse dosimetry from spot measurements from health surveys. This doctoral study revealed that the impact of multi-routes co-exposures on IV of toxicokinetics may depend on the compounds in the mixtures and the level of exposure to these substances. For example, the variation obtained on the amount of substance metabolized by CYP2E1-based VIs based is about -9 to -5% and -38 to -33% for benzene respectively for 'low' and 'high' exposures simulated to the mixture. For VC and TCE, it is respectively about -17 to -13% and -20 to -11% for "high" exposures, and zero for "low" exposures to the mixture. The exposures to toluene in air estimated by reverse dosimetry in this thesis (median between 0.004 and 0.01 ppm) are well below the maximum guideline values recommended by Health Canada for chronic exposure and suggest an exposure of Canadian studied via indoor air. The uncertainty mentioned above varies between 15 and 23% in the context of our work. The present doctoral study has contributed to improving the assessment of the toxicological risk of VOCs.
Risk assessment Biomonitoring data Physiologically-based pharmacokinetic modeling VOCs Monte Carlo simulations Interindividual variability chemical interactions